$0.5418
0.0091.69%
Last update: Nov 10, 7:48 PM
Akebia Therapeutics Inc
AKBANASDAQ
Akebia Therapeutics fell 68.1% from $1.67 to $0.53, behind the S&P 500's +10.0%. Its worst day was Nov 5 (−38.8%), and its low came Nov 6 at $0.40.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $0.00 beat the $-0.02 estimate on $58.8M revenue (est. $57.5M).
0.0% · S&P 500 +1.6%
EPS of $-0.05 beat the $-0.05 estimate on $57.6M revenue (est. $47.9M).
Story events cover the past 12 months · Times ET
+9.1% · S&P 500 −0.6%
EPS of $-0.03 missed the $-0.01 estimate on $53.5M revenue (est. $52.6M).
−20.3% · S&P 500 −0.3%
EPS of $-0.03 beat the $-0.03 estimate on $49.1M revenue (est. $49.5M).
−26.0% · S&P 500 −0.2%
Akebia Therapeutics shares rose 15.8%, while the S&P 500 rose 0.3%.
+15.8% · S&P 500 +0.3%
EPS of $-0.05 missed the $-0.03 estimate on $36.9M revenue (est. $46.9M).
−38.8%, the year's worst day · S&P 500 −4.4%
Where it ended: a close of $0.53 on Nov 9, 2026. Up next: Q4 2026 earnings on Feb 25, 2027 (EPS est. $-0.03, revenue est. $34.5M).
Nothing in the past 12 months.
All AKBA dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for AKBA and SPY from Benzinga historical bars. Not investment advice.
